Likuiditas cepet actiniumpharma.com (ATNM)

Actinium Pharmaceuticals (ATNM) management enjoys market confidence driven by progress in late-stage trials and the establishment of a distribution network. The company focuses on developing radiotherapy to combat leukemia, which will ensure a steady stream of free cash flow in the future. The current market quotes visualized below, where the indicator stands at 3.88, complement the development picture of radio-immunotherapy, which awaits FDA approval and the expansion of applications in bone marrow transplantation.

This metric measures the business's ability to instantaneously settle short-term liabilities using cash and accounts receivable, completely excluding illiquid inventories. By analyzing the acid-test ratio, an investor determines the real margin of safety for Actinium Pharmaceuticals (ATNM), which is critically important given the company's high dependence on external nuclear reactors and third-party radiopharmaceutical facilities for isotope production.